Can you take Bivalirudin with Caplacizumab?
1 drug interaction and 5 additional warnings found for the following 2 drugs:
- bivalirudin
- caplacizumab
Drug interactions
Major drug interactions
Major:
bivalirudin caplacizumab
Applies to: bivalirudin and caplacizumab
Using caplacizumab together with bivalirudin may increase the risk of bleeding complications.
Talk to your doctor if you have any questions or concerns.
You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications.
You should seek immediate medical attention if you experience any unusual bleeding or bruising, or have other signs and symptoms of bleeding such as:
- dizziness
- lightheadedness
- red or black, tarry stools
- coughing up or vomiting fresh or dried blood that looks like coffee grounds
- severe headache
- weakness
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Disease interactions
5 potential interactions Applies to: 4 conditions, including Liver Disease, Bleeding Disorder, Renal Dysfunction, and Coagulation Defects and Disorders.
Bleeding Disorder
Major:
bivalirudin
Bivalirudin has a major potential interaction with Bleeding Disorder.
The use of thrombin inhibitors is contraindicated in the presence of active major bleeding. Additionally, these drugs should be used with caution in patients with disease states associated with an increased risk of bleeding.
Coagulation Defects and Disorders
Major:
bivalirudin
Bivalirudin has a major potential interaction with Coagulation Defects and Disorders.
The use of thrombin inhibitors is contraindicated in the presence of active major bleeding. Additionally, these drugs should be used with caution in patients with disease states associated with an increased risk of bleeding.
Moderate:
caplacizumab
Caplacizumab has a moderate potential interaction with Coagulation Defects and Disorders.
Caplacizumab increases the risk of bleeding. This risk is increased in patients with underlying coagulopathies (e.g., hemophilia, other coagulation factor deficiencies). It is also increased with concomitant use of drugs affecting hemostasis and coagulation. Treatment with caplacizumab should be interrupted if clinically significant bleeding occurs. Caution and close monitoring is advised.
Liver Disease
Moderate:
caplacizumab
Caplacizumab has a moderate potential interaction with Liver Disease.
No formal studies with caplacizumab have been conducted in patients with severe acute or chronic hepatic impairment and no data regarding the use of the drug in these populations are available. Due to a potential increased risk of bleeding, the use of caplacizumab in patients with severe hepatic impairment requires close monitoring.
Renal Dysfunction
Moderate:
bivalirudin
Bivalirudin has a moderate potential interaction with Renal Dysfunction.
Clinical studies showed that the clearance of bivalirudin is reduced approximately 20% with moderate and severe renal impairment and is reduced about 80% in dialysis-dependent patients. The infusion dose of bivalirudin may need to be reduced, and anticoagulant status monitored in patients with renal impairment.
Report options
More resources
bivalirudin
A total of 164 drugs are known to interact with bivalirudin.
- Bivalirudin is in the drug class thrombin inhibitors.
- Bivalirudin is used to treat the following conditions:
caplacizumab
A total of 166 drugs are known to interact with caplacizumab.
- Caplacizumab is in the drug class platelet aggregation inhibitors.
- Caplacizumab is used to treat Thrombotic Thrombocytopenic Purpura.
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.